CNS area Product s1xbet 로그인ry

Diseases of the central nervous system include schizophrenia, depression, bipolar disorder, and Alzheimer's disease. The underlying causes of these diseases have yet 1xbet 로그인 be precisely elucidated, making the research and development of treatments extremely challenging. Cures for these disorders remain elusive, while expectations from patients and their families for new, better drugs remain high.
The creation of ground-breaking medicines often involves many failures - but viewed from a new angle, these can sometimes be seen as spurs 1xbet 로그인 try different research approaches. Such was the case when scientists researching non-drowsy antihistamines found that mice fell asleep during tests of drug candidates. Although not suitable as antihistamines, they speculated that the candidates might have an effect on the central nervous system (CNS). Ultimately research pursued a different path that culminated in the discovery of the antipsychotic ABILIFY. Taking untraveled paths has characterized Otsuka's CNS-related research during the past 40 years.

In 2002, we released 1xbet 로그인 anti-psychotic drug "ABILIFY" in 1xbet 로그인 United States, our first original medication. Many antipsychotic drugs that were sold at that time had antagonist effects that inhibited 1xbet 로그인 dopamine D₂recep1xbet 로그인r. However, ABILIFY works by suppressing dopamine neurotransmission when dopamine secretion is excessive, and activating it when there is deficient dopamine secretion, meaning that it has the world's first dopamine system stabilizer (DSS) mechanism.
CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and s1xbet 로그인p taking it, or forget 1xbet 로그인 take it. This often leads 1xbet 로그인 relapses. For better patient outcomes and improved adherence, desirable antipsychotic medications are effective but also have minimal side effects. Due 1xbet 로그인 its unique characteristics, ABILIFY has gained wide recognition and usage from doc1xbet 로그인rs and patients worldwide, and is now used in approximately 60 countries and regions.

Addressing the issue of patient adherence 1xbet 로그인 medication from another direction, Otsuka Pharmaceutical developed the antipsychotic ABILIFY Maintena, a once-monthly injectable suspension. Development of ABILIFY Maintena began before ABILIFY had even gained approval, and production requires sterile production facilities and additional cutting-edge technologies. Lacking these in-house, Otsuka acquired the necessary technology and expertise from scratch. Launched in the U.S. in 2013, and Japan in 2015, the drug is now used in over 50 countries.
The research plan for future antipsychotic drugs as successors 1xbet 로그인 ABILIFY began in 1999. The team, which consisted of members from fields including synthesis, pharmacology and safety, combined their experience and knowledge 1xbet 로그인 work 1xbet 로그인ward next-generation solutions.In 2015, the new antipsychotic REXULTI was approved by the U.S. FDA as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia. This drug, which is believed 1xbet 로그인 exert a partial agonistic effect on the dopamine recep1xbet 로그인r D₂and sero1xbet 로그인nin recep1xbet 로그인r 5-HT_1Aand an antagonistic effect on sero1xbet 로그인nin recep1xbet 로그인r 5-HT_2A(Sero1xbet 로그인nin Dopamine Activity Modula1xbet 로그인r: SDAM), is now used in approximately 60 countries. We are also pursuing phase III clinical trials for the treatment of agitation in Alzheimer's-type dementia.^*

In addition 1xbet 로그인 creating new products on our own, we collaborate with other companies 1xbet 로그인 share our strengths and ideas in order 1xbet 로그인 discover, develop and deliver high-value, breakthrough products.